Adaptive Randomization of Neratinib in Early Breast Cancer
2016 · New England Journal of Medicine · 456 citations
https://doi.org/10.1056/nejmoa1513750
T
Tufia C. Haddad
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
270
Papers
5.7K
Citations
36
h-index
88
i10-index
Tufia C. Haddad is an academic researcher from Mayo Clinic in Arizona. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology. The author has an h-index of 36, co-authored 230 publications.
ORCID: 0000-0001-8226-3581Papers by this author
worksNOTCH3 expression is linked to breast cancer seeding and distant metastasis
2018 · Breast Cancer Research · 83 citations
https://doi.org/10.1186/s13058-018-1020-0
Function, Shoulder Motion, Pain, and Lymphedema in Breast Cancer With and Without Axillary Web Syndrome: An 18-Month Follow-Up
2018 · Physical Therapy · 69 citations
https://doi.org/10.1093/ptj/pzy010
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer
2023 · JAMA Oncology · 49 citations
https://doi.org/10.1001/jamaoncol.2022.7949
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
2021 · Annals of Oncology · 45 citations
https://doi.org/10.1016/j.annonc.2021.02.011
Clinicopathologic features of breast cancers that develop in women with previous benign breast disease
2015 · Cancer · 38 citations
https://doi.org/10.1002/cncr.29766
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat